Skip to main content

Advertisement

SpringerLink
Log in

Psychopharmacology in the 1990s

What Does the Future Hold for the Aged Patient?

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Agnoli A, Martucci N, Fabbrini G, Buckley AE, Fioradanti M. Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia 1: 109–114, 1990

    Google Scholar 

  • Ames DJ, Bhathal PS, Davies BM, Fraser JRE, Gibson PR, et al. Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. Australian and New Zealand Journal of Medicine 20: 193–195, 1990

    Article  PubMed  CAS  Google Scholar 

  • Bowen DM. Treatment of Alzheimer’s disease: molecular pathology versus neurotransmitter-based therapy. British Journal of Psychiatry 157: 327–330, 1990

    Article  PubMed  CAS  Google Scholar 

  • Brayne C, Ames D. The epidemiology of mental disorders in old age. In Gearing et al. (Eds) Mental health problems in old age, pp. 10–26, John Wiley & Sons, Chichester, 1988

    Google Scholar 

  • Bridges P. The drug treatment of depression in old age. In Murphy (Ed.) Affective disorders in the elderly, pp. 97–119, Churchill Livingstone, Edinburgh, 1986

    Google Scholar 

  • Brodaty H. Rejuvenation with KH3: fact or fantasy? Current Therapeutics 30: 15–23, 1989

    Google Scholar 

  • Brodaty H. The use of THA for Alzheimer’s disease. Correspondence. Medical Journal of Australia 152: 614, 1990

    PubMed  CAS  Google Scholar 

  • Bruno G, Mohr E, Gillespie M. Muscarinic agonist therapy of Alzheimer’s disease. Archives of Neurology 43: 659–661, 1986

    Article  PubMed  CAS  Google Scholar 

  • Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. British Journal of Psychiatry 157: 72–94, 1990

    Article  PubMed  CAS  Google Scholar 

  • Burns A, Levy R, Jacoby R. Diagnosing dementia: do we get it right? British Medical Journal 297: 1403–1404, 1988

    Article  Google Scholar 

  • Callingham BA. MAO inhibitors, old and new: similarities and differences. Clinical Neuropharmacology 13(Suppl. 2): 192–193, 1990

    Google Scholar 

  • Chatellier G, Lacomblez L. Tacrine and lecithin in senile dementia of the Alzheimer type: a multicentre trial. British Medical Journal 300: 495–499, 1990

    Article  PubMed  CAS  Google Scholar 

  • Copeland JRM, Dewey ME, Wood N, Searle R, Davidson IA, et al. Range of mental illness among the elderly in the community: prevalence of Liverpool using the GMS-AGECAT package. British Journal of Psychiatry 150: 815–823, 1987

    Article  PubMed  CAS  Google Scholar 

  • Davies B, Andrewes D, Stargatt R, Ames D, Tuckwell V, et al. Tetrahydroaminoacridine in Alzheimer’s disease. International Journal of Geriatric Psychiatry 5: 317–321, 1990

    Article  Google Scholar 

  • Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2: 1403, 1976

    Article  PubMed  CAS  Google Scholar 

  • Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease. Lancet 337: 989–992, 1991

    Article  PubMed  CAS  Google Scholar 

  • Flynn P, McLean S. Drugs in dementia. Current Therapeutics 30: 65–77, 1990

    Google Scholar 

  • Harrell LE, Jape RS, Falgout J, Callaway R, Avery C, et al. Biological and neuropsychological characterisation of physostigmine responders and non-responders in Alzheimer’s disease. Journal of the American Geriatrics Society 38: 113–122, 1990

    PubMed  CAS  Google Scholar 

  • Henderson AS, Jorm A. The problem of dementia in Australia, 2nd ed., Australian Government Publishing Service, Canberra, 1990

    Google Scholar 

  • Hermann C, Stern RG, Losonzcy MF, Jaff S, Davidson M. Diagnostic and pharmacological approaches in Alzheimer’s disease. Drugs & Aging 1: 144–162, 1991

    Article  CAS  Google Scholar 

  • Higgitt A. Indications for benzodiazepine prescriptions in the elderly. International Journal of Geriatric Psychiatry 3: 239–243, 1988

    Article  Google Scholar 

  • Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatrica Scandinavica 76: 465–479, 1987

    Article  PubMed  CAS  Google Scholar 

  • Lader M. Psychopharmacology of old age. In Levy & Post (Eds) The psychiatry of late life, pp. 143–162, Blackwell Scientific, Oxford, 1982

    Google Scholar 

  • Lindesay J, Briggs K, Murphy E. The GUY’s/AGE CONCERN Survey. Prevalence rates of cognitive impairment, depression and anxiety in an urban elderly community. British Journal of Psychiatry 155: 317–329, 1989

    PubMed  CAS  Google Scholar 

  • Little A, Levy R, Chuaqui-Kidd P, Hand D. A double blind, placebo controlled trial of high-dose lecithin in Alzheimer’s disease. Journal of Neurology, Neurosurgery and Psychiatry 48: 736–742, 1985

    Article  CAS  Google Scholar 

  • McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS/ADRDA work group under the auspices of Department of Health and Human Services Taskforce on Alzheimer’s disease. Neurology 34: 939–944, 1984

    Article  PubMed  CAS  Google Scholar 

  • Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomised clinical trial of daily aspirin therapy in multi infarct dementia. Journal of the American Geriatrics Society 37: 549–555, 1989

    PubMed  CAS  Google Scholar 

  • Mouradian MM, Mohr E, Williams JA, Chase TN. No response to high-dose muscarinic agonist therapy in Alzheimer’s disease. Neurology 38: 606–608, 1988

    Article  PubMed  CAS  Google Scholar 

  • Myers JK, Weissman MM, Tischler GL, Holzer CE, Leaf PJ, et al. Six-month prevalence of psychiatric disorders in three communities. Archives of General Psychiatry 41: 959–967, 1984

    Article  PubMed  CAS  Google Scholar 

  • Park P. Aluminium ‘mop’ slows Alzheimer’s disease. New Scientist 1752: 4, 1991

    Google Scholar 

  • Perry E, Tomlinson B, Blessed G, Bergmann K, Gibson P, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. British Medical Journal 2: 1457–9, 1978

    Article  PubMed  CAS  Google Scholar 

  • Post F. Functional disorders: I: description, incidence and recognition. In Levy & Post (Eds) The psychiatry of late life, pp. 176–196, Blackwell Scientific, Oxford, 1982

    Google Scholar 

  • Post F. Course and outcome of depression in the elderly. In Murphy (Ed.) Affective disorders in the elderly, pp. 164–176, Churchill Livingstone, Edinburgh, 1986

    Google Scholar 

  • Raskind MA, Risse SC, Stevens C, Lampe TH. Dementia and antipsychotic drugs. Journal of Clinical Psychiatry 48(Suppl. 5): 16–18, 1987

    PubMed  Google Scholar 

  • Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer-type. British Journal of Psychiatry 154: 797–800, 1989

    Article  PubMed  CAS  Google Scholar 

  • Summers WK, Majorvski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in the long-term treatment of senile dementia, Alzheimer type. New England Journal of Medicine 315: 1241–1245, 1986

    Article  PubMed  CAS  Google Scholar 

  • Tariot PM, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, et al. Multiple dose arecoline infusions in Alzheimer’s disease. Archives of General Psychiatry 45: 901–905, 1988

    Article  PubMed  CAS  Google Scholar 

  • Tariot PM, Sunderland T, Weingartner H, Murphy DL, Welkowitz JA, et al. Cognitive effects of L-deprenyl in Alzheimer’s disease. Psychopharmacology 91: 489–495, 1987

    Article  PubMed  CAS  Google Scholar 

  • Tollefson GD. Short term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biological Psychiatry 27: 1133–1142, 1990

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Melbourne Department of Psychiatry, 7th Floor, Clinical Sciences Building, Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia

    David Ames (Senior Lecturer in the Psychiatry of Old Age) & Virginia Tuckwell

Authors
  1. David Ames
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Virginia Tuckwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ames, D., Tuckwell, V. Psychopharmacology in the 1990s. Drugs & Aging 1, 339–344 (1991). https://doi.org/10.2165/00002512-199101050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199101050-00001

Keywords

Search

Navigation